

Genetic Signatures Appoints Anne Lockwood as Managing Director

Genetic Signatures Limited [ASX:GSS] (“GSS” or the “Company”), a global molecular diagnostics company today announces that its Board of Directors has appointed Non-Executive Director Anne Lockwood as interim Managing Director.

The appointment strengthens the Company’s leadership team at an important time and places Genetic Signatures in a position of strength, underpinned by deep financial management, capital discipline and governance expertise.

Mrs Lockwood brings over 30 years’ experience across finance, risk management and audit, including deep expertise in mergers and acquisitions and capital market transactions across a range of industries. She was appointed to the Board of Genetic Signatures in October 2024.

Mrs Lockwood is the former Chief Financial and Commercial Officer of ASX-listed Integral Diagnostics Limited (ASX: IDX) and currently serves as Non-Executive Director at Symal Group Limited (ASX: SYL) and Coventry Group Limited (ASX: CYG) and will step down from her position as Non-executive Director of Mayne Pharma Group Limited (ASX: MYX) at the end of February 2026. Prior to this, she spent more than 20 years in accounting, corporate advisory and audit roles, including 18 years at Andersens and EY.

Mrs Lockwood holds a Bachelor of Commerce with Majors in Accounting and Law, is a Fellow of the Institute of Chartered Accountants and a Graduate of the Australian Institute of Company Directors.

In her role, Mrs Lockwood will work closely and collaboratively with newly appointed Chief Executive Officer, Maria Halasz, supporting execution of the Company’s strategy while maintaining strong financial oversight.

Mrs Lockwood will assume the role of Managing Director for a six-month period, after which the Board will review the Company’s longer-term management arrangements. Given Anne’s in depth experience as a CFO, the appointment of a permanent CFO will be deferred during this period.

As outlined in the Company’s recent announcement regarding the resignation of the former Chief Executive Officer and Chief Financial Officer, the Board has been highly focused on ensuring continuity, quality and cost discipline. This refreshed management structure delivers experienced leadership while also reducing key personnel costs and supporting value creation for shareholders.

The Board and management team remain focused on maximising shareholder returns, and the Company is well positioned to execute on its strategy.

Caroline Waldron, Chair of Genetic Signatures, commented:

“Anne’s appointment ensures the Company is exceptionally well supported from a financial, commercial and governance perspective during this transition period. Together with Maria Halasz, the Board believes this management team positions Genetic Signatures to execute its strategy from a position of strength, while remaining sharply focused on maximising shareholder returns.”

Anne Lockwood, incoming Managing Director of Genetic Signatures, commented:

“Genetic Signatures has a strong platform and clear strategic priorities. I look forward to working closely with Maria, the Board and our valued employees to ensure disciplined financial management, support strategic execution and help deliver sustainable long-term value for shareholders.”

Please refer to Appendix A (below) for details of Mrs Lockwood’s remuneration and employment arrangements in relation to her interim appointment.

– END –

Announcement authorised for release by the Board of Genetic Signatures Limited.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Caroline Waldron

Chair Genetic Signatures

caroline.waldron@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics company, specialising in detecting infectious diseases, using patented 3base® technology to simplify the genetic complexity of pathogen identification. Automated diagnostic workflows accurately screen for multiple infectious pathogens with similar symptoms, in a single test. Genetic Signatures’ unique solutions enable laboratories to enhance diagnostic workflow and efficiencies, while reducing costs. Rapid results support infection control, appropriate patient management and disease surveillance, improving healthcare outcomes. Genetic Signatures continues to expand its global presence with direct representation in Australia, the United States and Europe, alongside international distribution partnerships.

ANNEXURE A

The material terms of Mrs Lockwood's employment as interim Managing Director are summarised below:

KEY TERMS	DETAILS
Appointment and Commencement Date	2 March 2026
Term	Anne Lockwood's appointment as Interim Managing Director will commence on the commencement date and will continue until 2 September 2026, with the option to extend as agreed in writing between Mrs Lockwood and the Board.
Base Remuneration	Base remuneration of \$350,000 per annum, exclusive of superannuation. 30% of the base remuneration will be in the form of Service Rights to be issued to Mrs Lockwood at an agreed price of \$0.30 per right, pursuant to the Genetic Signatures Rights Plan. The issue of the Service Rights is subject to shareholder approval. If shareholder approval is not obtained, the Company will make Mrs Lockwood whole through a cash payment.
Short Term Incentive	Nil
Long Term Incentive	Nil
Termination	Either party may terminate the Contract on one (1) weeks' notice.